Identification of NME5 as a contributor to innate resistance to gemcitabine in pancreatic cancer cells

FEBS Journal

Volumn 279, Issue 7, 2012, Pages 1261-1273

  Li, Fu ^a   Hu, Gang ^a,b   Jiang, Zhenzhou ^a   Guo, Jingjing ^a   Wang, Ke ^b   Ouyang, Kedong ^b   Wen, Danyi ^b   Zhu, Minghua ^c   Liang, Jiaxin ^b   Qin, Xiaoran ^b   Zhang, Luyong ^a  

^a CHINA PHARMACEUTICAL UNIVERSITY   (China)

^b Shanghai Chem Partner Co Ltd   (China)

^c SECOND MILITARY MEDICAL UNIVERSITY   (China)

Author keywords

apoptosis; gemcitabine; innate resistance; NME5; pancreatic cancer

Indexed keywords

GEMCITABINE; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; APOPTOSIS; ARTICLE; CANCER CELL; CANCER CELL CULTURE; CELL CYCLE ARREST; CONTROLLED STUDY; DOWN REGULATION; DRUG SENSITIVITY; EX VIVO STUDY; FEMALE; GENE; GENE EXPRESSION REGULATION; GENE IDENTIFICATION; GENE OVEREXPRESSION; GENETIC SCREENING; HUMAN; HUMAN CELL; HUMAN TISSUE; IN VITRO STUDY; MOUSE; NME5 GENE; NONHUMAN; PANCREAS ADENOCARCINOMA; PRIORITY JOURNAL; PROTEIN BINDING; TUMOR XENOGRAFT;

ANIMALS; ANTIMETABOLITES, ANTINEOPLASTIC; APOPTOSIS; CELL CYCLE; CELL CYCLE CHECKPOINTS; CELL LINE, TUMOR; DEOXYCYTIDINE; DOWN-REGULATION; DRUG RESISTANCE, NEOPLASM; GENE KNOCKDOWN TECHNIQUES; HUMANS; MICE; MICE, SCID; NEOPLASM TRANSPLANTATION; NF-KAPPA B; NM23 NUCLEOSIDE DIPHOSPHATE KINASES; PANCREATIC NEOPLASMS;

EID: 84862777507     PISSN: 1742464X     EISSN: 17424658     Source Type: Journal    
DOI: 10.1111/j.1742-4658.2012.08521.x     Document Type: Article

References (43)

1. Jemal A, Bray F, Center MM, Ferlay J, Ward E, &, Forman D, (2011) Global cancer statistics. CA Cancer J Clin 61, 69-90.
2. Jemal A, Siegel R, Xu J, &, Ward E, (2010) Cancer statistics, 2010. CA Cancer J Clin 60, 277-300.
3. Yang L, Parkin DM, Ferlay J, Li L, &, Chen Y, (2005) Estimates of cancer incidence in China for 2000 and projections for 2005. Cancer Epidemiol Biomarkers Prev 14, 243-250.
4. Stathis A, &, Moore MJ, (2010) Advanced pancreatic carcinoma: current treatment and future challenges. Nat Rev Clin Oncol 7, 163-172.
5. Schneider G, Siveke JT, Eckel F, &, Schmid RM, (2005) Pancreatic cancer: basic and clinical aspects. Gastroenterology 128, 1606-1625.
6. O'Reilly EM, &, Abou-Alfa GK, (2007) Cytotoxic therapy for advanced pancreatic adenocarcinoma. Semin Oncol 34, 347-353.
7. Burris HA III, Moore MJ, Andersen J, Green MR, Rothenberg ML, Modiano MR, Cripps MC, Portenoy RK, Storniolo AM, Tarassoff P, et al. (1997) Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: a randomized trial. J Clin Oncol 15, 2403-2413.
8. Kim MP, &, Gallick GE, (2008) Gemcitabine resistance in pancreatic cancer: picking the key players. Clin Cancer Res 14, 1284-1285.
9. Crnogorac-Jurcevic T, Efthimiou E, Nielsen T, Loader J, Terris B, Stamp G, Baron A, Scarpa A, &, Lemoine NR, (2002) Expression profiling of microdissected pancreatic adenocarcinomas. Oncogene 21, 4587-4594.
10. Shrikhande SV, Kleeff J, Kayed H, Keleg S, Reiser C, Giese T, Buchler MW, Esposito I, &, Friess H, (2006) Silencing of X-linked inhibitor of apoptosis (XIAP) decreases gemcitabine resistance of pancreatic cancer cells. Anticancer Res 26, 3265-3273.
11. Moore PS, Sipos B, Orlandini S, Sorio C, Real FX, Lemoine NR, Gress T, Bassi C, Kloppel G, Kalthoff H, et al. (2001) Genetic profile of 22 pancreatic carcinoma cell lines. Analysis of K-ras, p53, p16 and DPC4/Smad4. Virchows Arch 439, 798-802.
12. Giroux V, Iovanna J, &, Dagorn JC, (2006) Probing the human kinome for kinases involved in pancreatic cancer cell survival and gemcitabine resistance. FASEB J 20, 1982-1991.
13. Sebastiani V, Ricci F, Rubio-Viqueira B, Kulesza P, Yeo CJ, Hidalgo M, Klein A, Laheru D, &, Iacobuzio-Donahue CA, (2006) Immunohistochemical and genetic evaluation of deoxycytidine kinase in pancreatic cancer: relationship to molecular mechanisms of gemcitabine resistance and survival. Clin Cancer Res 12, 2492-2497.
14. Hu G, Li F, Ouyang K, Xie F, Tang X, Wang K, Han S, Jiang Z, Zhu M, Wen D, et al. (2012) Intrinsic gemcitabine resistance in a novel pancreatic cancer cell line. Int J Oncol 40, 798-806.
15. Desvignes T, Pontarotti P, Fauvel C, &, Bobe J, (2009) Nme protein family evolutionary history, a vertebrate perspective. BMC Evol Biol 9, 256-280.
16. Kimura N, Shimada N, Nomura K, &, Watanabe K, (1990) Isolation and characterization of a cDNA clone encoding rat nucleoside diphosphate kinase. J Biol Chem 265, 15744-15749.
17. Liu C, Liu J, Wang X, Mao W, Jiang L, Ni H, Mo M, &, Wang W, (2011) Prognostic impact of nm23-H1 and PCNA expression in pathologic stage I non-small cell lung cancer. J Surg Oncol 104, 181-186.
18. Chapman EJ, Kelly G, &, Knowles MA, (2008) Genes involved in differentiation, stem cell renewal, and tumorigenesis are modulated in telomerase-immortalized human urothelial cells. Mol Cancer Res 6, 1154-1168.
19. Gibson S, &, Shillitoe EJ, (2006) Analysis of apoptosis-associated genes and pathways in oral cancer cells. J Oral Pathol Med 35, 146-154.
20. Parris TZ, Danielsson A, Nemes S, Kovacs A, Delle U, Fallenius G, Mollerstrom E, Karlsson P, &, Helou K, (2010) Clinical implications of gene dosage and gene expression patterns in diploid breast carcinoma. Clin Cancer Res 16, 3860-3874.
21. Gupta SC, Kim JH, Prasad S, &, Aggarwal BB, (2001) Regulation of survival, proliferation, invasion, angiogenesis, and metastasis of tumor cells through modulation of inflammatory pathways by nutraceuticals. Cancer Metastasis Rev 29, 405-434.
22. Budihardjo I, Oliver H, Lutter M, Luo X, &, Wang X, (1999) Biochemical pathways of caspase activation during apoptosis. Annu Rev Cell Dev Biol 15, 269-290.
23. Yang J, Liu X, Bhalla K, Kim CN, Ibrado AM, Cai J, Peng TI, Jones DP, &, Wang X, (1997) Prevention of apoptosis by Bcl-2: release of cytochrome c from mitochondria blocked. Science 275, 1129-1132.
24. Thomas A, El Rouby S, Reed JC, Krajewski S, Silber R, Potmesil M, &, Newcomb EW, (1996) Drug-induced apoptosis in B-cell chronic lymphocytic leukemia: relationship between p53 gene mutation and bcl-2/bax proteins in drug resistance. Oncogene 12, 1055-1062.
25. Zhu ZX, Zhang WM, Jia G, &, Zhou J, (2010) Effects of gemcitabine and pemetrexed on the proliferation of pancreatic cancer cell lines BXPC-3 and PANC-1 in vitro. Nan Fang Yi Ke Da Xue Xue Bao 30, 149-152.
26. Lawrence TS, Chang EY, Hahn TM, &, Shewach DS, (1997) Delayed radiosensitization of human colon carcinoma cells after a brief exposure to 2′,2′-difluoro-2′-deoxycytidine (Gemcitabine). Clin Cancer Res 3, 777-782.
27. Santini V, Bernabei A, Gozzini A, Scappini B, Zoccolante A, D'Ippolito G, Figuccia M, &, Ferrini PR, (1997) Apoptotic and antiproliferative effects of gemcitabine and gemcitabine plus Ara-C on blast cells from patients with blast crisis chronic myeloproliferative disorders. Haematologica 82, 11-15.
28. Kunnumakkara AB, Guha S, Krishnan S, Diagaradjane P, Gelovani J, &, Aggarwal BB, (2007) Curcumin potentiates antitumor activity of gemcitabine in an orthotopic model of pancreatic cancer through suppression of proliferation, angiogenesis, and inhibition of nuclear factor-kappaB-regulated gene products. Cancer Res 67, 3853-3861.
29. Arlt A, Gehrz A, Muerkoster S, Vorndamm J, Kruse ML, Folsch UR, &, Schafer H, (2003) Role of NF-kappaB and Akt/PI3K in the resistance of pancreatic carcinoma cell lines against gemcitabine-induced cell death. Oncogene 22, 3243-3251.
30. Sharma S, Neale MH, Di Nicolantonio F, Knight LA, Whitehouse PA, Mercer SJ, Higgins BR, Lamont A, Osborne R, Hindley AC, et al. (2003) Outcome of ATP-based tumor chemosensitivity assay directed chemotherapy in heavily pre-treated recurrent ovarian carcinoma. BMC Cancer 3, 19-28.
31. Cree IA, Kurbacher CM, Untch M, Sutherland LA, Hunter EM, Subedi AM, James EA, Dewar JA, Preece PE, Andreotti PE, et al. (1996) Correlation of the clinical response to chemotherapy in breast cancer with ex vivo chemosensitivity. Anticancer Drugs 7, 630-635.
32. Sheikh R, Walsh N, Clynes M, O'Connor R, &, McDermott R, (2010) Challenges of drug resistance in the management of pancreatic cancer. Expert Rev Anticancer Ther 10, 1647-1661.
33. Lacombe ML, Wallet V, Troll H, &, Veron M, (1990) Functional cloning of a nucleoside diphosphate kinase from Dictyostelium discoideum. J Biol Chem 265, 10012-10018.
34. Hoffmann R, &, Valencia A, (2004) A gene network for navigating the literature. Nat Genet 36, 664.
35. Bult CJ, Eppig JT, Kadin JA, Richardson JE, &, Blake JA, (2008) The Mouse Genome Database (MGD): mouse biology and model systems. Nucleic Acids Res 36, D724-D728.
36. Steeg PS, Bevilacqua G, Kopper L, Thorgeirsson UP, Talmadge JE, Liotta LA, &, Sobel ME, (1988) Evidence for a novel gene associated with low tumor metastatic potential. J Natl Cancer Inst 80, 200-204.
37. Rayet B, &, Gelinas C, (1999) Aberrant rel/nfkb genes and activity in human cancer. Oncogene 18, 6938-6947.
38. Deharvengt SJ, Gunn JR, Pickett SB, &, Korc M, (2010) Intratumoral delivery of shRNA targeting cyclin D1 attenuates pancreatic cancer growth. Cancer Gene Ther 17, 325-333.
39. Kim HJ, Kim JC, Min JS, Kim MJ, Kim JA, Kor MH, Yoo HS, &, Ahn JK, (2011) Aqueous extract of Tribulus terrestris Linn induces cell growth arrest and apoptosis by down-regulating NF-kappaB signaling in liver cancer cells. J Ethnopharmacol 136, 197-203.
40. Gassler N, Zhang C, Wenger T, Schnabel PA, Dienemann H, Debatin KM, Mattern J, &, Herr I, (2005) Dexamethasone-induced cisplatin and gemcitabine resistance in lung carcinoma samples treated ex vivo. Br J Cancer 92, 1084-1088.
41. Li F, He L, Song ZQ, Yao JC, Rao XP, &, Li HT, (2008) Cytotoxic effects and pro-apoptotic mechanism of TBIDOM, a novel dehydroabietylamine derivative, on human hepatocellular carcinoma SMMC-7721 cells. J Pharm Pharmacol 60, 205-211.
42. Kharbanda S, Pandey P, Jin S, Inoue S, Bharti A, Yuan ZM, Weichselbaum R, Weaver D, &, Kufe D, (1997) Functional interaction between DNA-PK and c-Abl in response to DNA damage. Nature 386, 732-735.
43. Bafna S, Kaur S, Momi N, &, Batra SK, (2009) Pancreatic cancer cells resistance to gemcitabine: the role of MUC4 mucin. Br J Cancer 101, 1155-1161.